StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) stock

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3051% below fair value
$3.82−0.31 (-7.51%)

Close on Nov 16, 2026Market cap $120.03MP/E –Yield –

LENZ Therapeutics cash

Cash and short-term investments held at the end of each period.

LENZ Therapeutics's cash was $220.00M at Jun 30, 2026. For fiscal 2025 it was $292.30M, up 39.8% from the year before. The highest annual figure on record is $376.98M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$292.30M+39.8%
FY2024Dec 31, 2024$209.10M+13.5%
FY2023Dec 31, 2023$184.30M-35.0%
FY2022Dec 31, 2022$283.60M-24.8%
FY2021Dec 31, 2021$376.98M+1805.7%
FY2020Dec 31, 2020$19.78M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$220.00M+5.0%
Q1 FY2026Mar 31, 2026$258.40M+33.1%
Q4 FY2025Dec 31, 2025$292.30M+39.8%
Q3 FY2025Sep 30, 2025$202.20M-6.9%
Q2 FY2025Jun 30, 2025$209.60M+6.9%
Q1 FY2025Mar 31, 2025$194.10M-9.0%
Q4 FY2024Dec 31, 2024$209.10M+13.5%
Q3 FY2024Sep 30, 2024$217.20M-7.2%
Q2 FY2024Jun 30, 2024$196.10M-20.5%
Q1 FY2024Mar 31, 2024$213.30M+80764761.8%
Q4 FY2023Dec 31, 2023$184.30M-35.0%
Q3 FY2023Sep 30, 2023$234.00M-23.3%
Q2 FY2023Jun 30, 2023$246.70M-24.9%
Q1 FY2023Mar 31, 2023$264-100.0%
Q4 FY2022Dec 31, 2022$283.60M-24.8%
Q3 FY2022Sep 30, 2022$305.10M-22.7%
Q2 FY2022Jun 30, 2022$328.30M-14.0%
Q1 FY2022Mar 31, 2022$352.10M+98.9%
Q4 FY2021Dec 31, 2021$376.98M+1805.7%
Q3 FY2021Sep 30, 2021$394.80M+3644.3%
Q2 FY2021Jun 30, 2021$381.97M+2701.8%
Q1 FY2021Mar 31, 2021$177.02M–
Q4 FY2020Dec 31, 2020$19.78M–
Q3 FY2020Sep 30, 2020$10.54M–
Q2 FY2020Jun 30, 2020$13.63M–

More LENZ Therapeutics figures

See a number that looks wrong?